Introduction
Acinetobacter spp. is important opportunistic pathogen in nosocomial infections, which cause a wide range of clinical complications, such as pneumonia, septicemia and meningitis, especially in immunocompromised patients and intensive care units (ICUs). In recent years, new antibacterial agents are needed for the treatment of infections caused by multidrugresistant (MDR) Acinetobacter spp., including broadspectrum beta (β)-lactams, aminoglycosides, and uoroquinolones (Falagas et al., 2008; Manchanda et al., 2010; Neonakis et al., 2011) . Tigecycline was recently approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency for the treatment of complicated skin and intra-abdominal infections. Tigecycline, the 9-tert-butyl-glycylamido derivative of minocycline, exhibits a broad-spectrum of activity against numerous pathogens, including Acinetobacter spp.. Like the tetracyclines, tigecycline binds to the 30S subunit of bacterial ribosomes and inhibits protein synthesis by preventing the incorporation of amino acid residues into elongating peptide chains (Fraise, 2006; Neonakis et al., 2011; Peterson, 2008) .
However, many researches indicated that there was a discrepancy in the susceptibility results of tigecycline against Acinetobacter spp. among di erent methods of testing such as broth microdilution, E-test, disc di usion, and automated systems. Reference standard, broth microdilution testing serves as the method of comparison for the development and evaluation of alternative susceptibility testing methodologies. Recently, an E-test has been developed for the susceptibility testing of tigecycline. However, defined susceptibility breakpoints have not been declared thus far for A. baumannii in the latest issues of the Clinical and Laboratory Standarts Institute (CLSI) because of insufficient data about clinical usage of tigecycline (Liu et al., 2010; Neonakis et al., 2011; Shakoor et al., 2011) . e unavailability of standard breakpoints of tigecycline leads to mistakes in categorization of MIC values and consequently gives rise to careless use of this antibiotic (Shakoor et al., 2011) . e first aim of the present study was to investigate the antimicrobial activity of tigecycline by disc di usion A b s t r a c t e present study aimed to evaluate antimicrobial activity of tigecycline against 84 multidrug resistant (MDR) Acinetobacter spp. strains by disc di usion and E-test methods. e results of disc di usion test were compared according to two di erent interpretation ways. In addition, E-test results and the disc di usion results that interpreted by both the methods were checked for compatibility. According to the disc di usion test, 3 strains (3.57%) were found resistant to tigecycline when considering breakpoints suggested by Food and Drug Administration (FDA). On the other hand, none of the strains was found resistant to the evaluation criteria recommended by Jones et al. (2007) . Considering E-test results of tigecycline, MIC 50 and MIC 90 values of tigecycline for Acinetobacter spp. were 0.75 and 1 mg/l, respectively. Based on FDA defined breakpoints for Enterobacteriaceae, any resistant isolate was detected. In conclusion, although there are some di erences in the results, tigecycline was found quite e ective on Acinetobacter spp. isolates with reference to the both disc di usion and the E-test methods.
K e y w o r d s: Acinetobacter, antibiotic resistance, tigecycline 296 method and the E-test for 84 clinical MDR Acinetobacter sp., and the second one was to compare the susceptibility assessment methods. e isolates were identified and antimicrobial susceptibilities were determined by BD Phoenix System. MDR Acinetobacter spp. were defined as the isolates resistant to at least three classes of antimicrobial agents. e isolates were stored at -80°C, in the Brain Heart Infusion broth (Oxoid) supplemented with 10% glycerin.
Experimental

Material and Methods
Bacteria
Disc di usion method. In vitro susceptibility of Acinetobacter spp. against tigecycline was determined by Kirby-Bauer disc di usion method according to the CLSI guidelines, by using 15 μg tigecycline discs (Becton Dickinson, USA) (CLSI). e results were evaluated by using disc di usion breakpoints for Enterobacteriaceae proposed by FDA (susceptible ≥ 19 mm and resistant ≤ 14 mm) and by Jones et al. (2007) (susceptible ≥ 16 mm and resistant ≤ 12 mm). Escherichia coli ATCC 25922 was used as control strain.
E-test method. E-test Tigecycline gradient strips (AB Biodisc, Sweden; 0.016-256 μg/ml) were used according to CLSI guidelines and the MIC values were interpreted according to FDA defined breakpoints for Enterobacteriaceae (susceptible ≤ 2 mg/l; intermediate 4 mg/l; resistant ≥ 8 mg/l) were applied in this study. MICs were read at 100% inhibition of growth. E. coli ATCC 25922 was used as the control strain.
Statistical analysis. Statistical analysis was performed using Minitab statistical so ware (Minitab Release 16 © , State College, PA). For comparison of the evaluation criteria and antibiotic susceptibility tests results, Z test was employed. In all tests, di erences were considered significant when p < 0.05.
Results
is study showed that 3 Acinetobacter spp. strains (3.57%) were resistant according to a disc di usion method when considering breakpoints suggested by FDA. None of the strains was found resistant in the disc di usion results according to Jones' criteria. Similarly, E-test method results showed no resistance in the Acinetobacter spp. strains. On the other hand, the susceptibility rate detected by the E-test method was statistically higher than the disc di usion method according to both interpretation criteria (p < 0.05) ( Table I) . e tigecycline MIC range was found as 0.032-3 mg/l by E-test method. MIC 50 and MIC 90 values of tigecycline for Acinetobacter spp. were 0.75 and 1 mg/l, respectively (Table II) . 
Discussion
Recently, some researches on in vitro activity of tigecycline against Acinetobacter showed a variability depending on the methodology used to determine susceptibility. For example, microdilution testing methodologies can show potent in vitro activity for tigecycline against MDR Acinetobacter spp., on the other hand the E-test can indicate high tigecycline resistance among clinical isolates (Kulah et al., 2009; Shakoor et al., 2011; Wang and Dowzicky, 2010) . In this study, all the Acineto bacter sp. isolates were found to be susceptible to tigecycline although there were some di erences in the results of the E-test and disc di usion assays. Besides, E-test susceptibility results were supported by disc diffusion results when the recommendations by Jones et al. (2007) were considered (p < 0.05), and the MICs of the isolates did not exceed 3 mg/l. Wang and Dowzicky (2010) found low MIC 90 values (≤ 2 mg/l) for tigecycline against Acinetobacter spp. isolates from blood samples, as similar studies published before. ey also pointed out the deficiency of suggested breakpoints for tigecycline against Acinetobacter spp., thus comparing susceptibility studies based on di erent guides leads to confusing or even misleading results. When considereding the FDA breakpoint for Enterobacteriaceae, tigecycline inhibited at least 90.0% of isolates from all countries (Mendes et al., 2010) .
In the east part of Turkey, of 71 A. baumannii strains studied, 2 strains (3%) were resistant, 35 strains (49%) moderately susceptible, and 34 strains (48%) susceptible against tigecycline according to the disk di usion breakpoints proposed by FDA for Enterobacteriaceae and 1 strain (1%) was resistant, 1 strain (1%) moderately susceptible, and 69 strains (97%) susceptible when considered the breakpoints according to Jones et al. us, it was asserted that the use of FDA criteria for tigecycline against Acinetobacter spp. was inaccurate, and also breakpoints suggested by Jones et al. should be supported by further investigations (Gülhan et al., 2009) . Bolmstrom et al. (2007) showed that the tigecycline E-test gradient method was as accurate as the reference methods. In addition, the error rates were very low. Hope et al. (2007) determined that tigecycline E-tests were shown to have good correlation with agar dilution MICs. However, amlikitkul et al. (2007) indicated that there was a discrepancy in the susceptibility results of tigecycline against Acinetobacter spp. among di erent methods of testing. e MICs determined by the E-test were usually four-fold higher than those determined by the broth microdilution method. Similarly, Pillar et al. (2008) observed a four-fold increase in MIC 90 value among tested A. baumannii by E-test relative to broth microdilution test and noted a difference between the two testing methodologies. Liu et al. (2010) compared the results of E-test and broth microdilution method for tigecycline susceptibility testing of 393 A. baumannii isolates collected from 19 hospitals in Taiwan. E-test results showed an agreement in 76.6% of the strains when compared with the broth microdilution method. According to the results they declared that the E-test is not ideal as a substitute for broth microdilution testing in determining the MICs of tigecycline against A. baumannii isolates. Zarate et al. (2010) assayed in parallel by the broth microdilution, agar dilution, and disc di usion method in 60 MDR Acinetobacter spp. isolates obtained from hospitalized patients at two teaching hospitals in Argentina. A comparative analysis between methods by scattergram correlation and analysis of MICs and diameter zones around the disk was performed.
ey found a positive lineal correlation between the methodologies. Using the FDA Enterobacteriaceae susceptibility breakpoint for tigecycline, an acceptable minor error rate was observed by agar dilution and broth microdilution, but an unacceptable error by the disc di usion method. In another study from Pakistan (Shakoor et al., 2010) , in vitro activity of tigecycline against 100 Acinetobacter spp. were determined by E-test and the MICs were interpreted according to both the BSAC and FDA breakpoints. eir data has changed significantly from 94% sensitive to 79% non-susceptible (intermediate or resistant), thus the authors underlined the importance of requirement universally compliant breakpoints for tigecycline against Acinetobacter spp.
Conclusions
Management of Acinetobacter spp. infections is difficult due to the emergence of isolates with multipledrug resistance. us, it is necessary to evaluate new molecules that are potentially useful against Acinetobacter spp. Tigecycline is seems to be a good choice for succeed in therapy. It is also an important to monitor the increase of the resistance in the micro organisms during the usage of tigecycline for treatment. e development and validation of reliable methods for antimicrobial susceptibility testing and MIC determinations of tigecycline are critical to clinical practice as well as for ongoing surveillance programs.
In many countries, agar dilution or broth microdilution method is recommended, because the tigecycline microdilution panel is still difficult to obtain on a large scale. e E-test strip can be set up as easily as a disc di usion test by most clinical laboratories without the need for specialized equipment.
e disc di usion data should be supported by broth microdilution tests and further studies should be conducted to minimize false-susceptible errors. It is also important to decide the evaluation criteria to determine the antibiotic susceptibility properly. Interpretive breakpoints for susceptibility reporting by clinical microbiology laboratories were previously set for an antimicrobial agent with no consideration of bacterial species di erences. In recent years such di erences have been appreciated and species-related interpretive breakpoints are issued more frequently. Moreover, further studies are needed to define the most adequate methods for testing tigecycline susceptibility in Acinetobacter sp.
